Back
EMDAAC
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π Esg
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual capital growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
10
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Emyria Limited - Option Expiring 22-Mar-2027 Deferred
π Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in EMDAAC
10
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in EMDAAC
N/A
EMDAAC investor breakdown
π΅ Income of investors
More than 200k
15%
150k - 200k
8%
100k - 150k
15%
50k - 100k
23%
Less than 50k
38%
πΆ Age of investors
18 - 25
26 - 34
20%
35 - 90
70%
π Legal gender of investors
Female
70%
Male
30%
Pearlers who invest in EMDAAC also invest in...
Emyria Ltd. is a healthcare technology and services company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2020-02-12. The firm is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyriaβs Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.
π Performance (5Yr p.a)
-8.24%
π Share price
$0.05 AUD
π¦ LOGISTICS
ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.
π Performance (5Yr p.a)
10.28%
π Share price
$36.03 AUD
π GLOBAL
πΈ FINANCIALS
π€ TECHNOLOGY
π HIGH PRICE GROWTH
VEU.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard All-World ex-US Shares Index ETF seeks to track the return of the FTSE All-World ex US Index before taking into account fees, expenses and tax
π Performance (5Yr p.a)
10.70%
π Share price
$107.91 AUD
π GLOBAL
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
Pilbara Minerals Ltd. engages in the provision of exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 877 full-time employees. The company went IPO on 2007-09-19. The firm owns 100% of an independent hard-rock lithium operation, the Pilgangoora operation in Australia, and the Colina Project in Brazil. Its Pilgangoora operation is located 140 kilometers (kms) from Port Hedland in Western Australiaβs resource rich Pilbara region on Nyamal and Kariyarra Country. Spodumene concentrate from its Pilgangoora operation is shipped from Port Hedland, the bulk export port, to lithium chemical converters primarily in China. The firm's Colina project is located 10 kms from the town of Salinas in the world class mining jurisdiction of Minas Gerais, Brazil. The firm is also integrated into the lithium value chain through its joint venture with POSCO in South Korea, which manufactures battery-grade lithium hydroxide.
π Performance (5Yr p.a)
108.81%
π Share price
$2.31 AUD
ποΈ SOCIALLY AWARE
βοΈ MINING
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
9.31%
π Share price
$109.85 AUD
π¦πΊ AUSTRALIA
π§± MATERIALS
β³οΈ DIVERSIFIED
π HIGH PRICE GROWTH
πΈ FINANCIALS
Want more shares? Try these...
Emyria Ltd. is a healthcare technology and services company. The company is headquartered in Leederville, Western Australia. The company went IPO on 2020-02-12. The firm is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyriaβs Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.
π Performance (5Yr p.a)
-8.24%
π Share price
$0.05 AUD
π¦ LOGISTICS